Literature DB >> 131729

Mouse strain difference in the expression of antitumor activity of PS-K.

C Yoshikumi, K Nomoto, K Matsunaga, T Fuji, K Takeya.   

Abstract

Effect of PS-K on tumor growth and antibody production was studied in inbred C57BL/6, SL, C3H/He, and AKR mice, and in colony-bred ICR mice. (1) PS-K exhibited antitumor activity on sarcoma-180 in ICR mice, but not in AKR mice. Growth of sarcoma-180 was suppressed to the intermediate extent in other strains. (2) In ICR strain, antibody production against trinitrophenyl was depressed in mice bearing sarcoma-180 and restored by PS-K. In AKR mice, on the other hand, antibody production was not depressed in tumor-bearing state and was not augmented by PS-K. Other strains showed intermediate degrees of suppression of antibody-producing capacity by sarcoma-180 and its restoration by PS-K.CR strain, the growth of Ehrlich tumor as the challenge tumor was enhanced in mice bearing sarcoma-180 as compared to that in controls. After the treatment with PS-K in this strain, however, not only the growth of sarcoma-180 but also of Ehrlich tumor was inhibited completely. On the other hand, the growth of Ehrlich tumor in AKR strain was neither enhanced in mice bearing sarcoma-180 nor inhibited by PS-K.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 131729

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  10 in total

1.  Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer.

Authors:  M Torisu; Y Hayashi; T Ishimitsu; T Fujimura; K Iwasaki; M Katano; H Yamamoto; Y Kimura; M Takesue; M Kondo
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Depression of protective mechanism during the early phase of a viral infection in tumor-bearing mice and prevention by PSK.

Authors:  S Tsuru; K Nomoto; M Taniguchi; H Fujisawa; Y Zinnaka
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Clinical value of immunochemotherapy with OK-432 or PS-K for stomach cancer patients.

Authors:  S Fujimoto; M Takahashi; T Minami; H Ishigami; M Miyazaki; K Itoh
Journal:  Jpn J Surg       Date:  1979-09

4.  Influence of PSK (Krestin) on resistance to infection of Pseudomonas aeruginosa in tumor-bearing mice.

Authors:  T Ando; I Motokawa; K Sakurai; Y Ohmura; T Fujii; K Matsunaga; C Yoshikumi; K Nomoto
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Preoperative serum immunosuppressive acidic protein (IAP) test for the prognosis of gastric cancer: a statistical study of the threshold level and evaluation of the effect of the biological response modifier PSK.

Authors:  J Sakamoto; A Koike; S Saji; S Teramukai; Y Ohashi; H Nakazato
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

6.  Antitumor activities and tumor necrosis factor producibility of traditional Chinese medicines and crude drugs.

Authors:  K Haranaka; N Satomi; A Sakurai; R Haranaka; N Okada; M Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide.

Authors:  M Kato; K Hirose; M Hakozaki; M Ohno; Y Saito; R Izutani; J Noguchi; Y Hori; S Okumoto; D Kuroda
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968

8.  Depression of macrophage functions and T-cell-mediated immunity to listeria infection in tumor-bearing mice and its prevention by PSK.

Authors:  S Tsuru; K Nomoto; M Taniguchi; H Kitani; M Watanabe; Y Zinnaka
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  Protective effect of biological response modifiers on murine cytomegalovirus infection.

Authors:  K Ebihara; Y Minamishima
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

10.  Role of first stimulating agents in the production of tumor necrosis factor.

Authors:  K Haranaka; N Satomi; A Sakurai; R Haranaka
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.